

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2 Revision Date: 26.09.2025 SDS Number: 657053-00023 Date of last issue: 14.04.2025
Date of first issue: 02.05.2016

Section 1: Identification

Product identifier : Tedizolid Injection Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD
Address : 50 Tuas West Drive
Singapore - Singapore 638408
Telephone : +1-908-740-4000
Emergency telephone number : 65 6697 2111 (24/7/365)
E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification

Classification of the substance or mixture

Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure : Category 2 (Bone marrow, Blood, Gastrointestinal tract)
Short-term (acute) aquatic hazard : Category 1
Long-term (chronic) aquatic hazard : Category 1

GHS Label elements, including precautionary statements

Hazard pictograms :

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Bone marrow, Blood, Gastrointestinal tract) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Tedizolid Phosphate	856867-55-5	>= 50 -< 70

Section 4: First-aid measures

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

In case of eye contact : Thoroughly clean shoes before reuse.
If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

Tedizolid Injection FormulationVersion
4.2Revision Date:
26.09.2025SDS Number:
657053-00023Date of last issue: 14.04.2025
Date of first issue: 02.05.2016

use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection**Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Tedizolid Phosphate	856867-55-5	TWA	400 µg/m ³ (OEB 2)	Internal

Appropriate engineering control measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Section 9: Physical and chemical properties

Appearance : (lyophilised)

Colour : white to off-white

Odour : odourless

Odour Threshold : No data available

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2 Revision Date: 26.09.2025 SDS Number: 657053-00023 Date of last issue: 14.04.2025
Date of first issue: 02.05.2016

pH	:	7.4 - 8.1
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

Section 10: Stability and reactivity

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

Acute toxicity

Not classified based on available information.

Components:

Tedizolid Phosphate:

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg LD50 (Mouse): > 2,000 mg/kg
Acute toxicity (other routes of administration)	: LD50 (Mouse): 256 - 274 mg/kg Application Route: Intravenous LD50 (Rat): 244 mg/kg Application Route: Intravenous LD50 (Dog): 200 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Components:**Tedizolid Phosphate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Tedizolid Phosphate:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 15 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 25 mg/kg body weight
Result: Reduced foetal weight, Skeletal malformations

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 15 mg/kg body weight
Result: Reduced foetal weight, Skeletal malformations

Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 2.5 mg/kg body weight
Result: Reduced foetal weight, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Bone marrow, Blood, Gastrointestinal tract) through prolonged or repeated exposure.

Components:**Tedizolid Phosphate:**

Target Organs : Bone marrow, Blood, Gastrointestinal tract
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Tedizolid Phosphate:**

Species : Rat, female
NOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Lymph nodes, thymus gland, Bone marrow

Species : Rat, male
NOAEL : 30 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone marrow, spleen, Lymph nodes, thymus gland

Species : Rat, female
NOAEL : 15 mg/kg
Application Route : Intravenous
Exposure time : 28 d
Target Organs : Gastrointestinal tract

Species : Rat, male
NOAEL : 30 mg/kg
Application Route : Intravenous
Exposure time : 28 d
Target Organs : Gastrointestinal tract

Species : Rat
NOAEL : 2 mg/kg

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2 Revision Date: 26.09.2025 SDS Number: 657053-00023 Date of last issue: 14.04.2025 Date of first issue: 02.05.2016

LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 6 Months

Species : Dog
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 28 d
Symptoms : Vomiting

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Tedizolid Phosphate:

Inhalation : Symptoms: Nausea, Headache, Diarrhoea, Vomiting, Dizziness
Ingestion : Symptoms: Nausea, Headache, Diarrhoea, Vomiting, Dizziness

Section 12: Ecological information

Toxicity

Components:

Tedizolid Phosphate:

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): 0.313 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.0632 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.03175 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.6 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2 Revision Date: 26.09.2025 SDS Number: 657053-00023 Date of last issue: 14.04.2025
Date of first issue: 02.05.2016

Method: OECD Test Guideline 209

NOEC: 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Tedizolid Phosphate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 2 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Stability in water : Hydrolysis: 0 %(5 d)

Bioaccumulative potential

Components:

Tedizolid Phosphate:

Partition coefficient: n-octanol/water : log Pow: 1.3

Mobility in soil

Components:

Tedizolid Phosphate:

Distribution among environmental compartments : log Koc: 5.23
Method: OECD Test Guideline 106

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number : UN 3077

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

UN proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Tedizolid Phosphate)

Transport hazard class(es) : 9
Packing group : III
Labels : 9
Environmental hazards : yes

IATA-DGR

UN/ID No. : UN 3077
UN proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Tedizolid Phosphate)
Transport hazard class(es) : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Tedizolid Phosphate)
Transport hazard class(es) : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subject to the requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations
Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

CA. DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 26.09.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be

SAFETY DATA SHEET



Tedizolid Injection Formulation

Version 4.2	Revision Date: 26.09.2025	SDS Number: 657053-00023	Date of last issue: 14.04.2025 Date of first issue: 02.05.2016
----------------	------------------------------	-----------------------------	---

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN